Odulimomab

From Infogalactic: the planetary knowledge core

Jump to: navigation, search

Odulimomab is an investigational drug for the prevention of transplant rejection^[1]^[2] and for the treatment of various immunological diseases.^[3]^[4]

It is a mouse monoclonal antibody directed against the alpha chain of the protein lymphocyte function-associated antigen 1 which is involved in immune reactions.^[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide Teriflunomide antifolate: Methotrexate
Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus Ciclosporin Pimecrolimus Abetimus Gusperimus
IMiDs	Lenalidomide Pomalidomide Thalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) TNF (Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab) Interleukin 5 (Mepolizumab) Immunoglobulin E (Omalizumab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab Ustekinumab)
Cellular target	CD3 (Muromonab-CD3 Otelixizumab Teplizumab Visilizumab) CD4 (Clenoliximab Keliximab Zanolimumab) CD11a (Efalizumab) CD18 (Erlizumab) CD20 (Obinutuzumab Rituximab Ocrelizumab Pascolizumab) CD23 (Gomiliximab Lumiliximab) CD40 (Teneliximab Toralizumab) CD62L/L-selectin (Aselizumab) CD80 (Galiximab) CD147/Basigin (Gavilimomab) CD154 (Ruplizumab) BLyS (Belimumab Blisibimod) CTLA-4 (Ipilimumab Tremelimumab) CAT (Bertilimumab Lerdelimumab Metelimumab) Integrin (Natalizumab) Interleukin-6 receptor (Tocilizumab) LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab Daclizumab Inolimomab) T-lymphocyte (Zolimomab aritox)
Unsorted	Atorolimumab Cedelizumab Fontolizumab Maslimomab Morolimumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Vapaliximab Vepalimomab

-cept (Fusion)

v t e Index of the immune system
Description	Physiology cells autoantigens autoantibodies complement surface antigens IG receptors
Disease	Allergies Immunodeficiency Immunoproliferative immunoglobulin disorders Hypersensitivity and autoimmune disorders Neoplasms and cancer
Treatment	Procedures Drugs antihistamines immunostimulants immunosuppressants monoclonal antibodies

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Ulocuplumab Varlilumab immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†
Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

v t e Index of the immune system
Description	Physiology cells autoantigens autoantibodies complement surface antigens IG receptors
Disease	Allergies Immunodeficiency Immunoproliferative immunoglobulin disorders Hypersensitivity and autoimmune disorders Neoplasms and cancer
Treatment	Procedures Drugs antihistamines immunostimulants immunosuppressants monoclonal antibodies

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Hidden categories: